Annual EBIT
-$496.92 M
+$121.96 M+19.71%
31 December 2023
Summary:
Apellis Pharmaceuticals annual earnings before interest & taxes is currently -$496.92 million, with the most recent change of +$121.96 million (+19.71%) on 31 December 2023. During the last 3 years, it has fallen by -$183.82 million (-58.71%). APLS annual EBIT is now -12231.62% below its all-time high of -$4.02 million.APLS EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$44.32 M
-$16.14 M-57.26%
30 September 2024
Summary:
Apellis Pharmaceuticals quarterly earnings before interest & taxes is currently -$44.32 million, with the most recent change of -$16.14 million (-57.26%) on 30 September 2024. Over the past year, it has increased by +$88.37 million (+66.60%). APLS quarterly EBIT is now -149.40% below its all-time high of $89.72 million, reached on 31 December 2020.APLS Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$211.54 M
+$88.37 M+29.47%
30 September 2024
Summary:
Apellis Pharmaceuticals TTM earnings before interest & taxes is currently -$211.54 million, with the most recent change of +$88.37 million (+29.47%) on 30 September 2024. Over the past year, it has increased by +$365.35 million (+63.33%). APLS TTM EBIT is now -7827.08% below its all-time high of -$2.67 million, reached on 30 September 2014.APLS TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
APLS EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +19.7% | +66.6% | +63.3% |
| 3 y3 years | -58.7% | +77.1% | +57.6% |
| 5 y5 years | -297.6% | +36.0% | +6.3% |
APLS EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -58.7% | +32.2% | -57.3% | +77.1% | at high | +71.1% |
| 5 y | 5 years | -297.6% | +32.2% | -149.4% | +79.4% | at high | +71.1% |
| alltime | all time | <-9999.0% | +32.2% | -149.4% | +79.4% | -7827.1% | +71.1% |
Apellis Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$44.32 M(+57.3%) | -$211.54 M(-29.5%) |
| June 2024 | - | -$28.18 M(-52.5%) | -$299.92 M(-22.3%) |
| Mar 2024 | - | -$59.29 M(-25.7%) | -$386.23 M(-22.3%) |
| Dec 2023 | -$496.92 M(-19.7%) | -$79.75 M(-39.9%) | -$496.91 M(-13.9%) |
| Sept 2023 | - | -$132.69 M(+15.9%) | -$576.89 M(-8.0%) |
| June 2023 | - | -$114.50 M(-32.6%) | -$627.11 M(-4.9%) |
| Mar 2023 | - | -$169.97 M(+6.4%) | -$659.65 M(+6.6%) |
| Dec 2022 | -$618.88 M(-15.5%) | -$159.72 M(-12.7%) | -$618.88 M(+2.5%) |
| Sept 2022 | - | -$182.92 M(+24.4%) | -$603.72 M(-1.7%) |
| June 2022 | - | -$147.04 M(+13.8%) | -$614.08 M(-10.0%) |
| Mar 2022 | - | -$129.19 M(-10.6%) | -$682.47 M(-6.9%) |
| Dec 2021 | -$732.76 M(+134.0%) | -$144.56 M(-25.2%) | -$732.76 M(+47.0%) |
| Sept 2021 | - | -$193.29 M(-10.3%) | -$498.48 M(+15.6%) |
| June 2021 | - | -$215.42 M(+20.0%) | -$431.39 M(+31.7%) |
| Mar 2021 | - | -$179.48 M(-300.0%) | -$327.67 M(+4.7%) |
| Dec 2020 | -$313.09 M(+4.6%) | $89.72 M(-171.1%) | -$313.09 M(-38.9%) |
| Sept 2020 | - | -$126.20 M(+13.0%) | -$512.10 M(+12.5%) |
| June 2020 | - | -$111.71 M(-32.3%) | -$455.12 M(+9.8%) |
| Mar 2020 | - | -$164.90 M(+50.9%) | -$414.34 M(+38.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | -$299.42 M(+139.6%) | -$109.29 M(+57.9%) | -$299.42 M(+32.6%) |
| Sept 2019 | - | -$69.22 M(-2.4%) | -$225.78 M(+17.9%) |
| June 2019 | - | -$70.93 M(+41.9%) | -$191.52 M(+24.9%) |
| Mar 2019 | - | -$49.98 M(+40.2%) | -$153.32 M(+23.2%) |
| Dec 2018 | -$124.99 M(+146.9%) | -$35.64 M(+1.9%) | -$124.41 M(+16.7%) |
| Sept 2018 | - | -$34.97 M(+6.8%) | -$106.63 M(+28.1%) |
| June 2018 | - | -$32.73 M(+55.3%) | -$83.25 M(+32.9%) |
| Mar 2018 | - | -$21.07 M(+18.0%) | -$62.65 M(+23.7%) |
| Dec 2017 | -$50.63 M(+86.7%) | -$17.86 M(+54.1%) | -$50.63 M(+28.8%) |
| Sept 2017 | - | -$11.59 M(-4.5%) | -$39.30 M(+12.5%) |
| June 2017 | - | -$12.13 M(+34.0%) | -$34.94 M(+53.2%) |
| Mar 2017 | - | -$9.05 M(+38.8%) | -$22.81 M(+65.8%) |
| Dec 2016 | -$27.12 M(+35.0%) | -$6.52 M(-9.9%) | -$13.76 M(-3.1%) |
| Sept 2016 | - | -$7.23 M(+3.9%) | -$14.20 M(+17.1%) |
| Dec 2015 | -$20.09 M(+77.9%) | -$6.96 M(+35.0%) | -$12.13 M(+50.1%) |
| Sept 2015 | - | -$5.16 M(+76.9%) | -$8.08 M(+44.6%) |
| Dec 2014 | -$11.29 M(+180.3%) | -$2.92 M(+9.3%) | -$5.59 M(+109.3%) |
| Sept 2014 | - | -$2.67 M | -$2.67 M |
| Dec 2013 | -$4.03 M | - | - |
FAQ
- What is Apellis Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals annual EBIT year-on-year change?
- What is Apellis Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals quarterly EBIT year-on-year change?
- What is Apellis Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals TTM EBIT year-on-year change?
What is Apellis Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of APLS is -$496.92 M
What is the all time high annual EBIT for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high annual earnings before interest & taxes is -$4.02 M
What is Apellis Pharmaceuticals annual EBIT year-on-year change?
Over the past year, APLS annual earnings before interest & taxes has changed by +$121.96 M (+19.71%)
What is Apellis Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of APLS is -$44.32 M
What is the all time high quarterly EBIT for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high quarterly earnings before interest & taxes is $89.72 M
What is Apellis Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, APLS quarterly earnings before interest & taxes has changed by +$88.37 M (+66.60%)
What is Apellis Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of APLS is -$211.54 M
What is the all time high TTM EBIT for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high TTM earnings before interest & taxes is -$2.67 M
What is Apellis Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, APLS TTM earnings before interest & taxes has changed by +$365.35 M (+63.33%)